StockWatch
·

Gala Precision Engineering Ltd Q2 FY27 Results

GALAPRECQ2 FY27 Results
Filing
Result:Good· Market: Flat#Margin expansion

Outlook: Cautiously Optimistic · Guidance: Maintained

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue93.7424.4%31.3%
Total Income95.0224.2%30.6%
Expenditure81.9322.8%29.8%
PBT13.0235.3%36.2%
Net Profit10.5829.2%26.1%
OPM16.72%0.67pp1.26pp
NPM11.13%0.43pp0.40pp
EPS8.2628.9%24.8%
View full financials

Industrials: 31% revenue growth with 26% adjusted PAT growth and OPM expansion (15.5%→16.7%) is healthy, above-average core growth, though NPM dipped slightly, keeping it short of a standout quarter.

GALA PRECISION · Q2 FY27 · THE VERDICT

31% Growth, Margins Lag, Guidance Unmoved

Gala beat Q2 revenue guidance handily but maintained full-year guidance rather than raising it—a cautious stance that reflects margin headwinds and execution risk ahead.

11 Nov 2026 · 6 min read
Reported Revenue

₹93.7 Cr

+31.3% YoY

FY27 Guidance

20–25% growth

Maintained, not raised

EBITDA Margin

16.7%

vs 17–19% target

Order Book

₹100+ Cr

+44% YoY

Gala Precision reported its strongest quarter in years—₹93.7 crore in revenue, up 31.3% year-on-year—and the order book crossed ₹100 crore for the first time. By any surface read, a blowout. Yet on the call, management reiterated full-year guidance (20–25% growth, 17–19% EBITDA margin) rather than raising it. That gap—the beat on the quarter, the unchanged outlook—is where the real story sits.

The volume story is real

Management broke down the 31% revenue growth into three roughly equal pillars: organic growth driven by volume (about 10%), new components sold to existing customers (about 10%), and new customer acquisition (about 10%). The order book grew 44% year-on-year, hitting ₹100 crore—a milestone that validates momentum across all three channels. Disc springs (DSS), the core product line, remains at 85% utilization; sheet fasteners, the newer segment, is expanding into offshore wind and auto. Electrolyzer—a new application market—generated a ₹2 crore order in H1 FY27, with ₹40–50 crore potential over 2–3 years if two more OEMs move from samples to orders.

But margins fell short of target

The tension emerges here. EBITDA margin landed at 16.7%—up 135 basis points year-on-year, a solid improvement—but below the 17–19% target management had guided. Why? Management cited two offsetting pressures: product mix is improving (good), and automation is helping manpower costs (good), but headcount additions for Europe and US market expansion are eating into those gains. H1 also benefited from no forex loss (versus a forex loss in H1 FY26), a tailwind unlikely to repeat in H2. The margin lag is not a one-off; it signals the near-term challenge: converting volume growth into margin recovery takes time.

Management claims vs. delivered results

Revenue growth 31% YoY from organic + new SKUs + new customer (3 pillars ~10% each)

Delivered ₹93.7 Cr, +31.3% YoY. Breakdown credible; each pillar validated.

Supported

Order book >₹100 Cr, 44% YoY growth

Cited as major milestone; 44% YoY growth is substantive and confirmed.

Supported

PAT ₹11 Cr at 11.31% margin

Delivered ₹10.6 Cr (+26.1% YoY), margin 11.1% per result. PAT slightly lower than claimed.

Slightly overstated

EBITDA margin 16.7%, targeting 17–19%

Delivered 16.7% OPM. Guidance range maintained from prior, not raised.

Supported

Chennai Phase 1 ramp to ₹15 Cr revenue from Q3; Phase 2 live Q4 FY27

Timeline credible given capex milestones. Phase 1 already live (Aug 2025); Phase 2 ₹50 Cr capacity on track.

Supported

On track for 25% revenue growth this year

Q2 delivered 31%, well above guidance midpoint. Statement aligns with range.

Supported

What changed on this call

Electrolyzer entry: First bulk order (₹2 Cr H1 FY27) secured from a global OEM; two more in sample-development stage. Opens structural upside (₹100+ crore customer potential over 2–3 years) but carries concentration risk: the ₹2 crore is single-source, not yet diversified. Order book inflection: Hit ₹100 crore for the first time. Management highlighted as a major milestone; 44% year-on-year growth is substantive and validates 3-channel strategy (organic, new SKU, new customer). Land acquisition: 10-acre parcel at Wada secured (MOU signed June 2026); legal finalization ~95% complete. Additional 3–5 acres being pursued via SIPCOT application (pending approval). Unlocks path to ₹550 crore capacity by end FY27 (vs. ₹450 crore today). Capacity milestones: Chennai Phase 1 live (Aug 2025); Phase 2 (₹50 crore capacity) targeted Q4 FY27. Phase 1 expected to ramp to ₹15 crore revenue run-rate from Q3. FY27 guidance maintained: Revenue growth 20–25%, EBITDA margin 17–19%, unchanged from prior call. Despite beating Q2 at 31%, management kept guidance unchanged—a cautious stance that flags execution risk on capacity ramp-ups and working capital headwinds.

The bull-bear ledger
  • Order book >₹100 Cr (44% YoY) validates 3-channel strategy

  • Electrolyzer ₹100+ Cr customer potential (₹2 Cr order in hand)

  • Capacity expansion concrete (Phase 1 live, Phase 2 Q4 FY27, Wada land secured)

  • Renewable-sector tailwind structural, not cyclical

  • EBITDA margin lagging target (16.7% vs 17–19%), recovery gradual

  • Working capital drag >₹11 Cr H1; KPMG fix benefits 1–1.5 years out

  • Guidance maintained despite beat suggests caution on H2 comps

  • Electrolyzer ₹2 Cr from single OEM; concentration risk real

  • Wada land approvals for 3–5 acres pending; execution risk on new sites

Risks ranked by severity for a holder

Margin recovery slower than guided

Medium

EBITDA margin at 16.7% vs 17–19% target. Manpower cost additions for market expansion offsetting product mix gains. If margin doesn't recover in Q3/Q4, consensus and ratings pressure will follow.

Execution risk on capacity ramp-ups

Medium

Chennai Phase 1 must hit ₹15 Cr revenue run-rate from Q3; Phase 2 live Q4 FY27. If either slips, FY27 revenue and margin guidance both at risk. Also depends on demand staying strong.

Working capital intensity into FY28

Medium

Inventory and receivables absorbed >₹11 Cr H1 cash due to 36% export mix (goods-in-transit) and 25% volume growth. KPMG fix 1–1.5 years away. If growth slows, working capital becomes a cash trap.

Electrolyzer customer concentration

Medium

₹2 Cr order in H1 from single OEM. ₹40–50 Cr potential over 2–3 years depends on 2 more OEMs moving from sample to order. If scaling stalls, upside evaporates.

Land acquisition delays at Wada

Low-Medium

10 acres secured; 3–5 more sought via SIPCOT application (pending approval). If SIPCOT delays, ₹550 Cr capacity target by Q4 FY27 is missed; alternate site would push timeline.

Forex headwind normalization in H2

Low

H1 saw no forex loss (vs H1 FY26 loss). 36% export revenue exposure. H2 currency normalization could offset margin tailwind.

Stock is overbought; near-ATH valuation

Low

RSI 72.4 (overbought); stock trading 15.66% below ATH. Margin lag could trigger profit-taking. Risk/reward near-term skews toward caution until Q3 data arrives.

How the street is positioned

The stock has rallied sharply: up 85.98% from its 52-week low (₹671.2), though now 15.66% below its all-time high of ₹1480. At ₹1248.3, it trades above its 20-day (₹1087), 50-day (₹1082), and 200-day (₹947) moving averages—a bullish technical setup. However, the RSI at 72.4 signals overbought conditions; the beat may already be priced in. Institutional ownership is stable and modest: FII at 1.30%, DII at 5.78%, promoter 54.34%. No significant rotation or insider selling; a recent bulk transaction by NK Securities (buy at ₹1041.63 / sell at ₹1042.38) shows no directional signal. Volume is increasing, suggesting fresh demand, but near-ATH valuations leave little room for disappointment. The market's message: the growth story is believed, but execution now matters.

What to watch next
  • 1 · Q3 Chennai Phase 1 ramp-up

    Target is ₹15 crore revenue run-rate. Delivery here is the first real test of capacity expansion roadmap and demand sustainability. Miss signals execution risk on Phase 2 and broader capex plan.

  • 2 · EBITDA margin recovery trajectory

    Must move toward 17–19% target. If Q3 margin dips further, it flags that manpower additions and forex headwinds are structural, not transient. Margin recovery is the linchpin of the bull case.

  • 3 · Electrolyzer order scaling (2nd/3rd OEM transition)

    Sample stage must convert to orders by Q3/Q4. If the two additional OEMs remain in pilot phase, the ₹40–50 Cr upside becomes a 2026+ story, not 2027.

  • 4 · Working capital inflection

    H1 absorbed >₹11 Cr. If H2 shows further deterioration or flat trajectory, KPMG's 1–1.5 year timeline becomes a cash drag risk, not a recovery story.

Gala Precision is executing against a real growth thesis: order book inflection, sector tailwinds, and capacity expansion all validate the multi-year narrative. Yet the quarter also reveals the near-term challenge: volume growth is real, but margin recovery is lagging, and guidance maintenance (not an upgrade) suggests management sees execution and macro risk ahead.

This is not a step-change story; it is steady execution with margin recovery as the critical prove-out. The stock is fairly valued at near-ATH levels, pricing in the growth consensus. Hold pending Q3 delivery on Chennai ramp-up. The single number to track from here is EBITDA margin trajectory—if it moves toward the 17–19% target, the bull case hardens; if it dips, the narrative fractures.

Informational and educational content only. Not investment advice.